Medicus Pharma Ltd
MDCX2.770USD
+0.340+13.99%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
44.14MCap. mercado
PérdidaP/E TTM
Más Datos de Medicus Pharma Ltd Compañía
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Información de la empresa
Símbolo de cotizaciónMDCX
Nombre de la empresaMedicus Pharma Ltd
Fecha de salida a bolsaOct 11, 2023
Director ejecutivoDr. Raza Bokhari, M.D.
Número de empleados12
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 11
Dirección100 King Street West
CiudadTORONTO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalM5X 1A4
Teléfono17323003046
Sitio Webhttps://medicuspharma.com/
Símbolo de cotizaciónMDCX
Fecha de salida a bolsaOct 11, 2023
Director ejecutivoDr. Raza Bokhari, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
Dr. Sara R. May, Ph.D.
Dr. Sara R. May, Ph.D.
Director
Director
--
--
Mr. Barry Fishman, CPA
Mr. Barry Fishman, CPA
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F Bonner
Ms. Carolyn F Bonner
President, Acting Chief Financial Officer
President, Acting Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 13 de sep
Actualizado: sáb., 13 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Velocity Fund Partners LP
13.97%
215 Capital Togo PHL Fund I, LP
9.84%
Interchange Capital Partners LLC
7.81%
Hathaway (John)
3.94%
Bokhari (Raza)
3.90%
Otro
60.54%
Accionistas
Accionistas
Proporción
Velocity Fund Partners LP
13.97%
215 Capital Togo PHL Fund I, LP
9.84%
Interchange Capital Partners LLC
7.81%
Hathaway (John)
3.94%
Bokhari (Raza)
3.90%
Otro
60.54%
Tipos de accionistas
Accionistas
Proporción
Corporation
23.81%
Individual Investor
12.09%
Investment Advisor
9.74%
Hedge Fund
0.46%
Research Firm
0.07%
Investment Advisor/Hedge Fund
0.02%
Otro
53.80%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
22
10.21M
64.09%
+108.37K
2025Q1
19
10.07M
84.39%
+1.61M
2024Q4
12
8.43M
77.76%
+1.48M
2024Q3
8
6.05M
68.59%
+2.33M
2024Q2
7
4.05M
50.15%
+329.10K
2024Q1
9
3.82M
47.35%
+3.82M
2023Q4
9
3.82M
47.35%
+3.82M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Velocity Fund Partners LP
2.91M
18.29%
+75.00K
+2.64%
Jun 02, 2025
215 Capital Togo PHL Fund I, LP
2.00M
12.55%
--
--
Jun 02, 2025
Interchange Capital Partners LLC
1.66M
10.43%
+204.71K
+14.05%
Mar 31, 2025
Hathaway (John)
800.95K
5.03%
--
--
Jun 02, 2025
Bokhari (Raza)
793.17K
4.98%
--
--
Jun 02, 2025
Melani (Kenneth)
334.41K
2.1%
-75.00K
-18.32%
Jun 02, 2025
Quinlan (James P)
129.15K
0.81%
--
--
Jun 02, 2025
Private Advisor Group LLC
56.75K
0.36%
+56.75K
--
Mar 31, 2025
Brennan (Edward Joseph JR)
86.50K
0.54%
--
--
Jun 02, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
